The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

Panelists discuss the importance of using liquid biopsy for detecting estrogen receptor 1 (ESR1) mutations rather than ...

Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in ...

A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to ...

Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without ...

Traditionally, HER2 status has been determined by immunohistochemistry (IHC) and in situ hybridization (ISH), distinguishing ...

T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib ...

The phase 2b SURVIVE trial of SurVaxM in newly diagnosed glioblastoma will continue as planned following an interim review by ...

Panelists discuss how innovative approaches to symptom monitoring incorporate multifaceted technology and team-based strategies, including electronic patient-reported outcome tools integrated with ...